Aging & Elder Health Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging & Elder Health Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AstraZeneca
Therapy for dementia in elderly, risk of cerebrovascular adverse event studied
April 10th, 2005
Data presented at the annual meeting of the American Association of Geriatric Psychiatry (AAGP) include results from a pooled analysis of 2 10-week placebo- controlled trials that examined Seroquel (quetiapine fumarate), developed by AstraZeneca, in elderly patients with dementia. The results of a safety analysis, which was performed as a secondary endpoint and assessed the risk of cerebrovascular adverse events (CVAEs) in elderly patients taking Seroquel, were presented by Lon S. Schneider, MD, professor of psychiatry, neurology, and gerontology, at the University of Southern California. These results suggest that Seroquel did not increase the risk...
Source: Aging & Elder Health Week (2005-04-10)
|
